Conflicting phase II efficacy data for Doxil.
Frykman
G
G
Williams
G
G
Pazdur
R
R
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000627:therapeutic use*; D017277:Drug Approval; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D004317:Doxorubicin